Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

Purpose: Targeted next-generation sequencing of DNA has become more widely used in
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …

Background Rearranged during transfection (RET) gene fusions are a validated target in
non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and …

The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …